Nutritional Status and Its Impact on Treatment Tolerance in Non-Small-Cell Lung Cancer Patients Receiving Osimertinib

被引：0
作者：
Barca-Diez, Claudia [1 ,2 ]
Palmeiro-Carballa, Regina [3 ]
Castro-Luaces, Susana [1 ,4 ]
Fortes-Gonzalez, Maria Susana [1 ,5 ]
Vazquez-Blanco, Silvia [5 ]
Martinez-Lopez-De-Castro, Noemi [1 ,4 ]
Lago-Rivero, Natividad [1 ,4 ]
机构：
[1] Univ Hosp Complex Vigo, Pharm Dept, Vigo 36312, Spain
[2] Univ Hosp Complex Pontevedra, Pharm Dept, Pontevedra 36071, Spain
[3] Univ Hosp Complex Vigo, Endocrinol & Nutr Dept, Vigo 36312, Spain
[4] SERGAS UVIGO, Galicia Hlth Res Inst IIS Galicia Sur, Innovat Clin Pharm Res Grp IFARMA Vigo, Vigo 36312, Spain
[5] Hosp Ribera Povisa, Pharm Dept, Vigo 36211, Spain
来源：
NUTRIENTS | 2025年 / 17卷 / 05期
关键词：
non-small-cell lung cancer; osimertinib; malnutrition; body composition; dose-limiting toxicities; sarcopenia; dynapenia; HEPATOCELLULAR-CARCINOMA; SORAFENIB; SARCOPENIA;
D O I：
10.3390/nu17050927
中图分类号：
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号：
100403 ;
摘要：
Background/Objectives: Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and is a leading cause of morbidity and mortality worldwide. Between 35% and 65% of NSCLC patients experience nutritional problems or malnutrition, which significantly affects their prognosis and quality of life. This study aims to describe the nutritional status and body composition of NSCLC patients treated with osimertinib, an oral tyrosine kinase inhibitor, while also assessing the prevalence of sarcopenia, presarcopenia, and dynapenia. Additionally, we explore the relationship between dose-limiting toxicities (DLTs) and nutritional status, as well as the impact of nutritional status on quality of life using the EQ-5D scale. Methods: A cross-sectional, observational study was conducted in 25 adult patients diagnosed with NSCLC treated with osimertinib under pharmacotherapeutic follow-up in the Pharmacy Consultations of a tertiary-level hospital. Anthropometric parameters, body composition (via bioimpedance analysis), and muscle functionality (via dynamometry) were assessed. Quality of life was evaluated using the EQ-5D scale. Results: The results showed that 36% of patients were malnourished, 4% had sarcopenia, 8% were presarcopenic, and 20% had dynapenia. Patients with DLTs exhibited significantly lower values of fat-free mass and the fat-free mass index, suggesting a relationship between low muscle mass and increased toxicities. Conclusions: These findings underscore the importance of early, individualized nutritional interventions in NSCLC patients treated with osimertinib to improve nutritional status and optimize oncological outcomes. Further research with larger cohorts and longitudinal designs is necessary to confirm these findings.
引用
收藏
页数：11
相关论文
共 15 条
  • [1] Pilikidou M., Palyvou F., Papadopoulou S.K., Tsiouda T., Tsekitsidi E., Arvaniti K., Miziou A., Tsingerlioti Z., Apostolidis G., Ntiloudis R., Et al., Lung cancer, treatment and nutritional status, Mol. Clin. Oncol, 15, (2021)
  • [2] Polanski J., Jankowska-Polanska B., Mazur G., Relationship between nutritional status and quality of life in patients with lung cancer, Cancer Manag. Res, 13, pp. 1407-1416, (2021)
  • [3] Cruz-Jentoft A.J., Bahat G., Bauer J., Boirie Y., Bruyere O., Cederholm T., Cooper C., Landi F., Rolland Y., Sayer A.A., Et al., Sarcopenia: Revised European consensus on definition and diagnosis, Age Ageing, 48, pp. 16-31, (2019)
  • [4] Rinninella E., Cintoni M., Raoul P., Ponziani F.R., Pompili M., Pozzo C., Strippoli A., Bria E., Tortora G., Gasbarrini A., Et al., Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: A systematic review and meta-analysis, Intern. Emerg. Med, 16, pp. 1341-1356, (2021)
  • [5] Antoun S., Birdsell L., Sawyer M.B., Venner P., Escudier B., Baracos V.E., Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study, J. Clin. Oncol, 28, pp. 1054-1060, (2010)
  • [6] Muscaritoli M., Arends J., Bachmann P., Baracos V., Barthelemy N., Bertz H., Bozzetti F., Hutterer E., Isenring E., Kaasa S., Et al., ESPEN practical guideline: Clinical Nutrition in cancer, Clin. Nutr, 40, pp. 2898-2913, (2021)
  • [7] Sawada K., Saitho Y., Hayashi H., Hasebe T., Nakajima S., Ikuta K., Fujiya M., Okumura T., Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment, JGH Open, 3, pp. 329-337, (2019)
  • [8] Hiraoka A., Hirooka M., Koizumi Y., Izumoto H., Ueki H., Kaneto M., Kitahata S., Aibiki T., Tomida H., Miyamoto Y., Et al., Muscle volume loss as a prognostic marker in hepatocellular carcinoma patients treated with sorafenib, Hepatol. Res, 47, pp. 558-565, (2017)
  • [9] Antonelli G., Gigante E., Iavarone M., Begini P., Sangiovanni A., Iannicelli E., Biondetti P., Pellicelli A.M., Miglioresi L., Marchetti P., Et al., Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment, United Eur. Gastroenterol. J, 6, pp. 1039-1048, (2018)
  • [10] Ministerio de Sanidad, Servicios Sociales e Igualdad. Ficha Técnica de TAGRISSO 80 mg Comprimidos Recubiertos con Película, (2022)
12